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OBJECTIVES: To assess cost-effectiveness of rituximab (RTX) 1st line maintenance
treatment compared to observation (O) in patients with follicular lymphoma (FL)
from the Polish public payer perspective. METHODS: Efficacy and safety of ritux-
imab 1st line maintenance therapy was assessed based on the results of systematic
review and the PRIMA clinical trial. Direct medical costs were assessed based on
the data regarding clinical practice of FL treatment and medical resources use
gathered in 5 oncology centers. The following costs were calculated and included:
drugs, drug administration, treatment-related adverse events, lymphoma relapse
treatment, patient health monitoring. A life-time horizon (25 years) and public
payer perspective were assumed. Costs were discounted at 5% and effects at 3.5%.
A four health state Markov model (progression-free 1st line, progression-free sub-
sequent line, progression and death) was used. Sensitivity analysis was performed
testing the influence of various critical parameters such as utilities values, differ-
ent costs categories, length of time horizon and patient’s body surface. RESULTS:
Introduction of 1st line maintenance therapy with RTX resulted in gain of 1.4 life
years and 1.3 quality adjusted life years compared to observation. The total incre-
mental costs were 60,707 PLN (1 EURO3.96 PLN) which corresponded to an incre-
mental cost-effectiveness ratio (ICER) of 43,348 PLN and an incremental cost-utility
ratio (ICUR) of 47,357 PLN. Both values were below 110 000 PLN cost-effectiveness
threshold assumed by the Polish public payer. The results were sensitive to dis-
count rates, utilities values applied to the specific health states, length of time
horizon. None of the tested scenarios resulted in values of ICUR and ICER exceeding
the 110,000PLN threshold, providing evidence that rituximab treatment is cost-
effective from public payer perspective. CONCLUSIONS: Rituximab in 1st line
maintenance treatment of FL is an effective, safe and cost -effective therapeutic
option.
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OBJECTIVES: To estimate the cost-effectiveness of cetuximab plus best supportive
care (BSC) or cetuximab plus chemotherapy in patients with EGFR-expressing
KRAS wild-type metastatic colorectal cancer who have failed at least two previous
chemotherapeutic regimens in the metastatic setting from the UK NHS
perspective. METHODS: A Markov model was developed to inform the cost-effec-
tiveness (CE) of cetuximab plus BSC and cetuximab plus chemotherapy both versus
BSC, and additionally the CE of cetuximab plus BSC and cetuximab plus chemo-
therapy both versus panitumumab plus BSC. Progression-free survival and overall
survival data were collected from the following clinical trials: Karapetis et al. 2008,
De Roock et al. 2007 and 2010, and Amado et al. 2008. These three clinical studies
were relevant to perform indirect treatment comparisons. RESULTS: In the base-
case analysis, treatments with cetuximab resulted in additional QALY as follows:
cetuximab plus BSC versus BSC (0.303), cetuximab plus chemotherapy versus BSC
(0.668), cetuximab plus BSC versus panitumumab plus BSC (0.193), and cetuximab
plus chemotherapy versus panitumumab plus BSC (0.616). The base-case incre-
mental cost effectiveness ratios (ICER) for cetuximab plus BSC and cetuximab plus
chemotherapy, both compared to BSC are in the region of £50,000 per QALY. Com-
pared to panitumumab plus BSC, the ICERs are below the NICE’s £30,000 willing-
ness-to-pay threshold. CONCLUSIONS:Weighting the QALYs gained with the NICE
supplementary advice, suggests that cetuximab plus BSC or cetuximab plus che-
motherapy is potentially a cost-effective use of NHS resources in this setting.
PCN88
ECONOMIC MODEL OF GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF)
IN PRIMARY (PP) AND SECONDARY PROPHYLAXIS (SP) OF FEBRILE
NEUTROPENIA (FN) IN NON-HODGKIN’S LYMPHOMA (NHL) PATIENTS
UNDERGOING CHEMOTHERAPY IN FRANCE
Perrier L1, Sebban C2, Leon N3, Maurel F4, Cohen-Nizard S5, De Liège F5
1Cancer Centre Léon Bérard, Lyon, France, 2Cancer Centre Leon Berard, Lyon, France, 3IMS
Health, Puteaux, France, 4IMS Health, Puteaux, France, France, 5Amgen France SAS, Neuilly-sur-
Seine, France
OBJECTIVES: To assess the cost-effectiveness in France of current G-CSF strategies
as PP (from first cycle and before an FN event) and SP (after an FN event) for NHL
patients receiving cytotoxic chemotherapy. METHODS: A Markov model was de-
veloped to calculate cost per FN events avoided, life-year saved (LYS), and quality
adjusted life year (QALY); results were expressed as incremental cost-effectiveness
ratios (ICERs). ICERs for 9 prophylaxis strategies were evaluated for three NHL
chemotherapies (CHOP, CHOP-R and ACVBP): PP or SP with pegfilgrastim (Neu-
lasta®), 6-day filgrastim (Neupogen®), 11-day filgrastim, 6-day lenograstim; and no
prophylaxis. All strategies were compared to no prophylaxis. FN-related outcomes
including FN-hospitalizations, FN-mortality and RDI were assessed using epidemi-
ologic data, utility and chemotherapy-related FN-risk (21% for CHOP-21, 19% for
RCHOP-21, 52% for ACVBP). Direct healthcare costs (G-CSF, administration, and
FN-related events) were calculated from French Health insurance perspective.
Costs and outcomes were discounted (4%/year). Based on international guidelines,
PP should be given to high-risk patients (FN risk320%). RESULTS: In the high che-
motherapy FN-risk population, pegfilgrastim was the most cost-effective G-CSF
compared to SP-pegfilgratim. For instance, in patients undergoing ACVBP chemo-
therapy, ICERs with PP-pegfilgrastim were €2,019 per FN avoided, €10,194 per QALY
gained and €8,632 per LYS versus SP-pegfilgrastim. In RCHOP-21 and without con-
sidering patient risk factors, if SP was considered instead of no prophylaxis, peg-
filgrastim was the dominant G-CSF with ICERs of €2,112 per FN avoided, €14,703 per
QALY gained and €11,940 per LYS versus no prophylaxis. CONCLUSIONS: With
French settings, pegfilgrastim is the most cost-effective PP-G-CSF in high chemo-
therapy FN-risk patients versus SP-pegfilgrastim. After an FN event, pegfilgrastim
is the most cost-effective SP-G-CSF versus no prophylaxis.
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OBJECTIVES: To assess the public health impact of the quadrivalent (6,11,16,18)
HPV vaccination program for São Paulo, Brazil.METHODS:A published mathemat-
ical model of the transmission dynamics of HPV infection and disease was adapted
for São Paulo, Brazil. The model captured direct protective effects of vaccination
and indirect effects (herd immunity). Model inputs were used from Brazil or the
Latin/America region when available; otherwise, the default values in the original
model were used. Maintaining current cervical cancer screening practices in Brazil,
we evaluated two strategies: routine vaccination of females by age 12 (S1), and S1
combined with a temporary (5 years) female catch-up program for age 12–24 years
(S2). The vaccine coverage rates were 85% for the routine and 95% by age 26 years
for the catch-up vaccination programs. RESULTS: Comparing S1 to no vaccination,
we estimated the cumulative percent (absolute cases) reduction in HPV 6/11/16/18-
related incident genital warts-female, genital warts-male, cervical intraepithelial
neoplasia (CIN) grade 1, CIN 2/3, cervical cancer cases, and cervical cancer deaths
would be 78% (2,488,240), 67% (2,166,770), 68% (360,235), 65% (1,154,566), 47%
(135,810), and 44% (39,147), respectively, over 100 years. Compared to S1, S2 pro-
vided additional cumulative percent (absolute cases) reduction of 9% (273,866), 11%
(357,728), 7% (39,455), 7% (131,861), 7% (19,620), and 7% (6,009) in HPV 6/11/16/18-
related incident genital warts-female, genital warts-male, CIN 1, CIN 2/3, cervical
cancer cases, cervical cancer deaths. CONCLUSIONS: A prophylactic quadrivalent
HPV vaccination program for females in Sao Paulo, Brazil can substantially reduce
the incidence of cervical cancer, CIN, and genital warts. Female catch up vaccina-
tion may provide greater reductions in HPV-related diseases.
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OBJECTIVES: Evaluate the cost-effectiveness analysis of erlotinib compared with
docetaxel and pemetrexed in the second-line treatment of advanced non-small-
cell-lung cancer (NSCLC) from a societal perspective in a Russian setting.
METHODS: A Markov state transition model, based on two randomized phase III
studies of erlotinib versus pemetrexed (HORTC) and pemetrexed versus docetaxel
(Nasse H. et al 2005), was used to estimate total direct costs and quality-adjusted
life years (QALYs). Data about cost of medical services and drugs are received from
the price-list of out-patient medical aid in clinic MMA of I.M.Sechenov 01.02.2011,
site minzdravsoc.ru//medicine and other accessible electronic resources. Costs,
effectivenesses, utilities were discounted at 3%. Sensitivity analysis for key param-
eters in the model was conducted. RESULTS: Erlotinib was associated with a re-
duction in total costs (1 179 452 roubles versus 1 260 607 roubles and 1 769 367
roubles) and improved outcomes (total QALYs of 0.299 versus 0.248 and 0.271) in
comparison with docetaxel and pemetrexed, respectively. Sensitivity analysis
showed that major factors influencing cost-effectiveness and cost-utility ratios are
survival gain, price of drugs, discount rates. CONCLUSIONS: In summary erlotinib
is more cost-effective in comparison with docetaxel and pemetrexed for second-
line treatment of advanced NSCLC due to lower adverse event and drug adminis-
tration costs.
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OBJECTIVES: This study is devoted on a comparative pharmacoeconomic analysis
regimes XELOX  BV (bevacizumab) versus XELOX  CET (cetuximab) treatment
(q3w); FOLFOX4  BV and FOLFOX4  CET (q2w) in the treatment of mCRC. The
efficacy and safety of combined treatment regimens based on the data of interna-
tional clinical trials. METHODS: Medical services were taken from the standards of
medical care for patients with ÑRC and their costs were based on the price-list of
Cancer Research Center. The cost analysis of anticancer and related drugs were
based on the information about limit selling/import prices of vital and essential
drugs. The main characteristics for Markov’s model were: the Markov states (with-
out progression, progression, death); a Markov’s cycle (1 month); the time horizon
(5 years). RESULTS: The cost of diagnosis was 16757 rubles, the medical services –
222802 rubles. The mCRC therapy as a first line by XELOX in combination with BV
was 1029694 rubles or with CET–1899867 ruble; FOLFOX4 in combination with BV–
1109402 rubles or with CET–2026917 rubles. The highest CER was for mode
XELOXCET-263870 rubles. The Markov’s model shows that the COST/QALY and
COST/LYG will above with each year, but in comparing groups with BV or CET
therapy in the next 5 years, it was shown a tendency of the increase in cost per
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